Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Cyclophosphamide 8Zoledronic Acid 5Therapeutics 5Flow Cytometry 5pembrolizumab 3fludarabine 3Specimen Handling 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Immunologic Techniques 3Gemcitabine 3Amplified Fragment Length Polymorphism Analysis 3venetoclax 2trametinib 2ruxolitinib 2pertuzumab 2palbociclib 2liposomal doxorubicin 2liposomal amphotericin B 2dabrafenib 2copanlisib 2aldesleukin 2abiraterone 2Vorinostat 2Trastuzumab 2Surveys and Questionnaires 2Sunitinib 2Sorafenib 2Rituximab 2Psychiatric Rehabilitation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × resiquimod × Plasma cell × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡